Studies on cyclic dipeptides, I: Aryl modifications ofcyclo-[Phe-His]
摘要:
Seven new cyclic dipeptides have been synthesized and tested for their applicability as tools to elucidate the mechanism of formation of mandelonitrile with (SS)-cyclo-[Phe-His] type catalysts. Conformational analyses based on H-1 NMR spectra are presented for all prepared cyclic dipeptides.
Studies on cyclic dipeptides, I: Aryl modifications ofcyclo-[Phe-His]
摘要:
Seven new cyclic dipeptides have been synthesized and tested for their applicability as tools to elucidate the mechanism of formation of mandelonitrile with (SS)-cyclo-[Phe-His] type catalysts. Conformational analyses based on H-1 NMR spectra are presented for all prepared cyclic dipeptides.
This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
[EN] SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS<br/>[FR] COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUES INHIBITEURS DU FACTEUR Xa
申请人:AVENTIS PHARMACEUTICALS PRODUCTS INC.
公开号:WO1999037304A1
公开(公告)日:1999-07-29
(EN) This invention is directed to oxoazaheterocyclyl compounds which inhibit factor Xa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of inhibiting factor Xa.(FR) L'invention porte sur des composés oxoazahétérocyclyle qui inhibent le facteur Xa, sur des compositions pharmaceutiques comprenant ces composés, sur des intermédiaires utiles dans la préparation de ces composés et sur un procédé d'inhibition du facteur Xa.
[EN] SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS<br/>[FR] COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUE INHIBITEURS DU FACTEUR Xa
申请人:AVENTIS PHARM PROD INC
公开号:WO2000032590A1
公开(公告)日:2000-06-08
This invention is directed to oxoazaheterocyclyl compounds which inhibit factor Xa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of inhibiting factor Xa.